Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have received a consensus rating of “Buy” from the ...

Rani Therapeutics also announced its anticipation for a Phase 1 clinical trial in 2025 for RT-114, an oral GLP-1/GLP-2 dual agonist for obesity treatment, developed in partnership with ProGen ...

To get a sense of who is truly in control of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), it is important to understand the ownership structure of the business. And the group that holds the ...

On February 5 th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of semaglutide using the RaniPill High ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and ...

Rani Therapeutics has a 12-month low of $1.24 and a 12-month high of $8.75. Insider Activity at Rani Therapeutics In other news, insider Kate Mckinley bought 17,960 shares of the stock in a ...

Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...